NCT05730712 2026-05-15Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate CancerMayo ClinicPhase 2 Completed7 enrolled 10 charts